Back to the main directory
EarningsReview / Equity
- Basilea Pharmaceutica - Cresemba milestone payment triggered by Edison Investment Research
- WANdisco - Starting 2023 with $6.6m telecom IoT win by Edison Investment Research
- 2023 Technology Outlook: Sorry to be picky... by BNP Paribas Exane
- Thinking on the Margin by BNP Paribas Exane
- Feng Tay Enterprises (9910 TT) by HSBC
- Taiwan Petrochemicals by HSBC
- Brazil and India in focus by BNP Paribas Exane
- Byggfakta Group (Hold, TP: SEK50.00) - ‘Show-me’ story after recent gains by DnB Markets
- Orkla (Hold, TP: NOK75.00) - Likely tepid Q4e by DnB Markets
- GARO (Buy, TP: SEK140.00) - Deep dive into AC charging market by DnB Markets
- Nordnet (Buy, TP: SEK174.00) - NII still a reason for excitement by DnB Markets
- Skanska (Buy, TP: SEK210.00) - Internal deals support Q4e by DnB Markets
- Danske Bank (Buy, TP: DKK175.00) - Attention turns to profitability by DnB Markets
- PGS (Sell, TP: NOK3.50) - Contract momentum continues by DnB Markets
- Chomping at the bit by BNP Paribas Exane
- BNPP Exane Deluxe Outlook for 2023 - Focus on China by BNP Paribas Exane
- December deliveries match our fears by BNP Paribas Exane
- Brothers in AuMs by BNP Paribas Exane
- Sapphire Rapids launches, finally by BNP Paribas Exane
- EQUITA SIM: SAES GETTERS (BUY ord./sav; unchanged) - Disposal of Medical Nitinol by Equita Sim
- Kicking on by BNP Paribas Exane
- Moment of Truth by BNP Paribas Exane
- Evolution (Buy, TP: SEK1650.00) - Leading the Live innovation by DnB Markets
- Storytel (Buy, TP: SEK103.00) - Audiobook thrill amid macro chill by DnB Markets
- Frontline (Buy, TP: NOK194.00) - Decoupled from Euronav by DnB Markets
- INVEST SECURITIES - TRANSGENE : OV doublement armé pour lutter contre le cancer - ACHAT, OC 5,7€ by Invest Securities
- Downgrade Intuit. Prefer Salesforce in 2023 by BNP Paribas Exane
- Better value elsewhere, and Figma uncertainty looms by BNP Paribas Exane
- KEFI Gold and Copper - New exploration and increased resources by Edison Investment Research
- Context Therapeutics - Manufacturing agreement with Lonza for CTIM-76 by Edison Investment Research
- A less ''appy new year by BNP Paribas Exane
- Otovo (Buy, TP: NOK41.00) - Lease monetisation approaching by DnB Markets
- Sinch (Buy, TP: SEK70.00) - On course for rebound in 2023 by DnB Markets
- Storebrand (Buy, TP: NOK109.00) - Set for AUM tailwind by DnB Markets
- Avanza Bank (Hold, TP: SEK202.00) - Slowing down by DnB Markets
- Axfood (Hold, TP: SEK295.00) - Inflation: the good, bad and ongoing by DnB Markets
- Ncc (Buy, TP: SEK130.00) - No residential exposure is a plus by DnB Markets
- Elkem (Hold, TP: NOK35.00) - Past the peak by DnB Markets
- Peab (Buy, TP: SEK73.00) - Consensus risk, but solid DPS by DnB Markets
- HusCompagniet - Resilient market leader at a cyclical discount by Danske Bank Equity Research
- Trends Tracker 4Q22: Brighter Horizons? by BNP Paribas Exane
- A road trip to sunnier prospects by BNP Paribas Exane
- 2023: steep, but no longer terrifying by BNP Paribas Exane
- Investment Daily 11/01/2023 by BNP Paribas Exane
- INVEST SECURITIES - DASSAULT SYSTEMES : Derating en grande partie réalisé mais risques à CT - NEUTRE vs VENTE, OC 35€ (vs 30€) by Invest Securities
- Better than feared, reluctant to extrapolate (and15 qs) by BNP Paribas Exane
- DSV - Initiation of coverage - Delivering Solid Value by DnB Markets
- Genmab (Sell, TP: DKK2750.00) - Cut to SELL on lower 2023e profits by DnB Markets
- Euronav (Buy, TP: USD18.20) - Decoupled from Frontline by DnB Markets
- Adevinta (Buy, TP: NOK100.00) - Volumes continuing to improve by DnB Markets